Table 3. Prescribing volume ratios of recently launched drugs.
| Group 5: Recently launched drugs | Country | Mean over period (since CDF or drug launcha) mg per 1000 pop | Prescribing volume ratio (95% CI) E vs Wb | P-value |
|---|---|---|---|---|
| Abiraterone | E | 463.69 | 0.78 (0.61–0.99) | 0.043 |
| W | 619.69 | 1.0 | ||
| Bendamustine | E | 1.12 | 0.75 (0.64–0.88) | 0.002 |
| W | 1.35 | 1.0 | ||
| Pazopanib | E | 62.32 | 0.51 (0.28–0.96) | 0.036 |
| W | 123.68 | 1.0 |
Abbreviations: CDF=Cancer Drugs Fund; CI=confidence interval; E=England; W=Wales.
a
Where the launch of the drug occurred after the introduction of the CDF, means are from drug launch: for example, Abiraterone September 2011.
b
These regression analyses are based on the period from the start of the CDF or drug launch (whichever came first) to the end of the study period. The prescribed volume ratio represents the rate of prescribing in England compared with Wales during this period.